Grifols S.A. (NASDAQ:GRFS) shares traded 6.00% higher at $10.60 on Wall Street last session.
In accordance with the data, 4 analysts cover Grifols S.A. (NASDAQ:GRFS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.52 and a low of $15.52, we find $15.52. Given the previous closing price of $10.00, this indicates a potential upside of 55.2 percent. GRFS stock price is now 15.64% away from the 50-day moving average and 28.44% away from the 200-day moving average. The market capitalization of the company currently stands at $8.84B.
It has been rated a hold by 1 analysts and a buy by 2. Brokers who have rated the stock have averaged $15.52 as their price target over the next twelve months.
There have been several recent changes in the stakes of large investors in GRFS stock. A new stake in Grifols S.A. shares was purchased by SHAY CAPITAL LLC during the first quarter worth $1,060,000. JUMP FINANCIAL, LLC invested $752,000 in shares of GRFS during the first quarter. In the first quarter, CAMPBELL & CO INVESTMENT ADVISER LLC acquired a new stake in Grifols S.A. valued at approximately $343,000. XTX TOPCO LTD acquired a new stake in GRFS for approximately $240,000. MERCER GLOBAL ADVISORS INC /ADV purchased a new stake in GRFS valued at around $216,000 in the second quarter. In total, there are 177 active investors with 42.60% ownership of the company’s stock.
Grifols S.A. (NASDAQ: GRFS) opened at $10.00 on Friday. During the past 12 months, Grifols S.A. has had a low of $5.71 and a high of $10.80. As of last week, the company has a debt-to-equity ratio of 1.71, a current ratio of 2.60, and a quick ratio of 0.80. According to the stock market information, the enterprise value for the company is $20.04B, which is based on a 30.29 price-to-earnings ratio, a 0.72 price-to-earnings-growth ratio, and a beta of 0.44. The fifty day moving average price for GRFS is $9.20 and a two-hundred day moving average price translates $8.28 for the stock.
The latest earnings results from Grifols S.A. (NASDAQ: GRFS) was released for Mar, 2023. The company reported revenue of $1.81 billion for the quarter, compared to $1.43 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 26.99 percent.
Moreover, the firm recently paid out its quarterly dividend on 06/14/2021. Investors who held shares on 06/04/2021 were paid a $0.456586 dividend. On an annualized basis, this represents a $0.66 dividend and a 6.21% percent yield. There was an ex-dividend date of 06/03/2021 for this dividend.
Grifols S.A.(GRFS) Company Profile
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally. The Biopharma segment provides plasma derivatives products, including Gamunex/Gamunex-C Immune Globulin Injection, Flebogamma Immune Globulin Intravenous, Xembify Immune Globulin Subcutaneous solution, HyperRAB Rabies Immune Globulin, Prolastin/Prolastin-C/Prolastin-C Liquid/Prolasplan/Prolastina/Pulmolast/Lynspad Alpha 1-Proteinase Inhibitor, Fanhdi and Alphanate, Antihemophilic Factor/von Willebrand factor Complex, Koate-DVI Antihemophilic Factor, Albutein/Albutein Flexbag/ Human Albumin Grifols/Plasbumin Albumin, and Vistaseal/Veraseal; and Tavlesse, a non-plasma derivative medicinal product. The Diagnostic segment offers transfusion medicine, which includes Procleix Panther systems/Procleix Panther with Automation Ready technology, Automated NAT blood screening systems, assays, software, WADiana/Erytra/Erytra Eflexys analyzers, BLOODchip ID/IDCore/IDHPA/IDRHD/IDCORE/BIDS, and antigens; and clinical and diagnostics products, such as Promonitor and Alpha1D. The Bio Supplies segment provides human biological materials for life sciences research and the development and manufacturing of pharmaceutical and diagnostic products. The Others segment offers healthcare solutions, which provides services and manufactures products, including parenteral solutions, robotics, and software used by hospitals, blood banks, plasma collection centers and other healthcare systems. The company’s products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. Grifols, S.A. has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products, and with GIANT and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1940 and is headquartered in Barcelona, Spain.
